News & Views
Milestone Payments Triggered following EC Approval
Jun 15 2021
UK pharmaceutical company Diurnal Group specialising in chronic endocrine (hormonal) diseases, has announced a payment of $1.0 million of a possible $1.25 from its China partner Citrine Medicine, following the recent European Commission’s (EC) approval for Efmody® (hydrocortisone modified-release hard capsules) and the attainment by Citrine of certain development milestones in China for Alkindi® (hydrocortisone granules in capsules for opening). This followed the company’s extension of its exclusive license agreement with Citrine covering Efmody® development in May 2021 to cover Efmody® and subsequently triggered the receiving the upfront payment.
Citrine, a therapeutics platform company focused on the Greater China market, has licensed the registration and commercialisation rights for the two products in China, Hong Kong, Taiwan and Macau and continues to plan for a New Drug Application (NDA) submission to the National Medical Products Administration in 2021 for Alkindi®.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).
Further information online
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan